Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Total Current Liabilities (2021 - 2025)

Goldenwell Biotech filings provide 4 years of Total Current Liabilities readings, the most recent being $39360.0 for Q3 2025.

  • On a quarterly basis, Total Current Liabilities changed N/A to $39360.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $39360.0, a N/A change, with the full-year FY2024 number at $1860.0, changed N/A from a year prior.
  • Total Current Liabilities hit $39360.0 in Q3 2025 for Goldenwell Biotech, down from $64360.0 in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $159266.0 in Q4 2021 to a low of $1860.0 in Q4 2024.
  • Median Total Current Liabilities over the past 4 years was $39856.0 (2022), compared with a mean of $61648.8.
  • The widest YoY moves for Total Current Liabilities: up 76.88% in 2022, down 76.88% in 2022.
  • Goldenwell Biotech's Total Current Liabilities stood at $159266.0 in 2021, then tumbled by 81.71% to $29126.0 in 2022, then tumbled by 93.61% to $1860.0 in 2024, then surged by 2016.13% to $39360.0 in 2025.
  • The last three reported values for Total Current Liabilities were $39360.0 (Q3 2025), $64360.0 (Q2 2025), and $1860.0 (Q4 2024) per Business Quant data.